Nabla

Active#11 worldwide · Clinical software

Clinical software

HQFrance

Last roundSeries C · Jun 2025

Uback rankings

Ranking	Tier	Rank	Edition	Next update
Clinical software · worldwide	Top 14	#11	Edition 0 (beta) · Sep 2026	22 Feb 2027

Rank historySep 2026 · #11 Clinical softwareFirst edition: no movements yet.

Estimated valuation

AI · Clinical software ranking (worldwide)

≈ USD 450MUSD 300–680M · Hundreds of M$ Medium confidence

Hundreds of k$

Millions $

Tens of M$

Hundreds of M$

Unicorn

Decacorn

Anchor: Last known equity round: Series C · USD 70M · Jun 2025

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Funding history

Date	Round	Amount	Type	Investors	Source
Jun 2025	Series C	USD 70M	Equity	HV Capital, DST Global	prnewswire.com

Rounds as cited by Uback’s rankings and their sources. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Nabla as a PDF, on one of three angles only:

ValuationWhat is Nabla worth?

Versus competitorsHow does it compare?

Who should acquire itStrategic buyers, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication and never change the rank.

Invest

Nabla is not open to Backers. A company opens only when a shareholder plans to sell or the company plans to raise.

Back the market instead: your intention joins a pool, passed to the local partner once it reaches critical mass.

Declare an interest in French startups Declare an interest in French healthtech Name Nabla as a preferred company (measures demand, promises nothing)

France poolBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until its pool is passed on. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run Nabla?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round. Claiming never changes the rank.

Claim this profile Report an upcoming round →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Press & investor announcements2 sources

Pappers (French company registry)Planned

Read by the AI at the next edition.

Comparable companies in clinical software

Full clinical software ranking →

Tandem Health#10SwedenHundreds of M$Suki#12United StatesHundreds of M$Qventus#9United StatesHundreds of M$Navina#13IsraelHundreds of M$

Investors in Nabla: HV Capital · DST Global

Sources. prnewswire.com · statnews.com

Last updated: Sep 2026Report an error

Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.